Effects of Gabexate Mesylate on the Gut Microbiota and Metabolomics in Rats with Sepsis.
gabexate mesylate
gut microbiota
metabolomics
rats
sepsis
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
10
2022
accepted:
12
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. However, there is still no single drug that could reduce septic mortality. Previous studies have reported gabexate mesylate (GM) significantly reduced serum inflammatory factors, alleviated sepsis-induced lung injury and improved clinical outcomes. This study aimed to combine with microbiome sequencing and metabolomics analysis to explore the effects of GM administration in septic rats. Sixty SD rats were randomly divided into the sham control (SC), cecal ligation and puncture (CLP), and GM injection (GM) groups. The mortality was measured and colonic feces were collected to examine the gut microbiota and metabolism 24 h after the procedure. The lung tissues were collected for hematoxylin-eosin staining. We observed the relative abundance of Pygmaiobacter, which contributed to short-chain fatty acids (SCFAs) promotion, Lactobacillus and Erysipelotrichaceae UCG-003 increased in the GM-treated rats, while Escherichia-Shigella and Akkermansia decreased compared to the sepsis-induced lung injury group. Furthermore, these 3 metabolites including Palmitoylethanolamide, Deoxycholic acid and Chenodeoxycholic acid correlated significantly to CLP- and GM-rich genus ( Our findings showed that GM attenuated sepsis-induced lung injury rats and regulated metabolites related to gut microbiota, which may provide an effective treatment for sepsis patients.
Sections du résumé
Background
UNASSIGNED
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. However, there is still no single drug that could reduce septic mortality. Previous studies have reported gabexate mesylate (GM) significantly reduced serum inflammatory factors, alleviated sepsis-induced lung injury and improved clinical outcomes. This study aimed to combine with microbiome sequencing and metabolomics analysis to explore the effects of GM administration in septic rats.
Methods
UNASSIGNED
Sixty SD rats were randomly divided into the sham control (SC), cecal ligation and puncture (CLP), and GM injection (GM) groups. The mortality was measured and colonic feces were collected to examine the gut microbiota and metabolism 24 h after the procedure. The lung tissues were collected for hematoxylin-eosin staining.
Results
UNASSIGNED
We observed the relative abundance of Pygmaiobacter, which contributed to short-chain fatty acids (SCFAs) promotion, Lactobacillus and Erysipelotrichaceae UCG-003 increased in the GM-treated rats, while Escherichia-Shigella and Akkermansia decreased compared to the sepsis-induced lung injury group. Furthermore, these 3 metabolites including Palmitoylethanolamide, Deoxycholic acid and Chenodeoxycholic acid correlated significantly to CLP- and GM-rich genus (
Conclusion
UNASSIGNED
Our findings showed that GM attenuated sepsis-induced lung injury rats and regulated metabolites related to gut microbiota, which may provide an effective treatment for sepsis patients.
Identifiants
pubmed: 36506782
doi: 10.2147/JIR.S392060
pii: 392060
pmc: PMC9733569
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6581-6594Informations de copyright
© 2022 Sun et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Clin Infect Dis. 2015 May 15;60 Suppl 2:S98-107
pubmed: 25922408
J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S116-8
pubmed: 18806700
Genomics Proteomics Bioinformatics. 2020 Dec;18(6):696-707
pubmed: 33607294
Mucosal Immunol. 2018 May;11(3):785-795
pubmed: 29067994
Thromb Res. 2017 Jan;149:38-44
pubmed: 27886531
J Surg Res. 2011 Jan;165(1):142-50
pubmed: 19766246
Front Pharmacol. 2020 Jun 17;11:902
pubmed: 32625095
Int J Mol Sci. 2021 Mar 10;22(6):
pubmed: 33802197
Bioresour Technol. 2022 Oct;361:127703
pubmed: 35907599
Stem Cell Res Ther. 2020 Sep 7;11(1):384
pubmed: 32894198
J Proteome Res. 2011 Dec 2;10(12):5512-22
pubmed: 21970572
Pak J Med Sci. 2013 Apr;29(2):490-4
pubmed: 24353562
Exp Cell Res. 2019 Oct 1;383(1):111465
pubmed: 31201811
J Appl Physiol (1985). 1990 Aug;69(2):694-9
pubmed: 1699920
Intensive Care Med. 2020 Aug;46(8):1552-1562
pubmed: 32572531
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3698-703
pubmed: 19234110
Gut Liver. 2012 Apr;6(2):256-61
pubmed: 22570757
Front Immunol. 2020 Jul 31;11:1331
pubmed: 32849494
Adv Nutr. 2018 Jan 1;9(1):21-29
pubmed: 29438462
Curr Ther Res Clin Exp. 2008 Aug;69(4):288-304
pubmed: 24692807
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Lipid Res. 2009 Aug;50(8):1509-20
pubmed: 19346331
Transl Pediatr. 2021 Jun;10(6):1647-1657
pubmed: 34295779
Crit Care Med. 1996 Jun;24(6):1047-53
pubmed: 8681572
Crit Care. 2018 Sep 27;22(1):239
pubmed: 30261905
Allergy. 2019 Apr;74(4):799-809
pubmed: 30390309
mSystems. 2020 Nov 3;5(6):
pubmed: 33144310
Cell Metab. 2017 Apr 4;25(4):856-867.e5
pubmed: 28380377
Sci Rep. 2019 Jan 22;9(1):287
pubmed: 30670726
Lancet Respir Med. 2016 Jan;4(1):59-72
pubmed: 26700442
Transplant Proc. 2012 Apr;44(3):817-9
pubmed: 22483504
Nat Commun. 2017 Nov 15;8(1):1512
pubmed: 29142211
Science. 2012 Jun 8;336(6086):1262-7
pubmed: 22674330
Microbiome. 2014 Jun 17;2:20
pubmed: 24967088
Microb Pathog. 2020 Mar;140:103956
pubmed: 31891794
J Immunol Res. 2020 Jul 31;2020:2340670
pubmed: 32802893
Inflamm Bowel Dis. 2011 Jun;17(6):1409-14
pubmed: 21560201
Crit Care Med. 2003 Apr;31(4):1147-53
pubmed: 12682486
Eur J Trauma Emerg Surg. 2015 Oct;41(5):531-8
pubmed: 26038004
Semin Thromb Hemost. 2000;26(1):39-42
pubmed: 10805280
Front Immunol. 2022 Sep 28;13:955654
pubmed: 36248790
PLoS Genet. 2007 Apr 27;3(4):e64
pubmed: 17465682
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Jan;34(1):28-34
pubmed: 35307057
Indian J Med Res. 2013 Dec;138(6):904-11
pubmed: 24521634
Gut. 1998 Aug;43(2):232-9
pubmed: 10189850
Biomed Pharmacother. 2017 Dec;96:1292-1298
pubmed: 29174575
Curr Opin Crit Care. 2017 Apr;23(2):167-174
pubmed: 28092309
Food Funct. 2021 Apr 7;12(7):3191-3205
pubmed: 33735338
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Gut. 2018 Jan;67(1):108-119
pubmed: 27802154
Arch Dis Child Fetal Neonatal Ed. 2020 Jul;105(4):380-386
pubmed: 31666311
Food Chem Toxicol. 2020 Apr;138:111237
pubmed: 32145354
Int J Mol Sci. 2020 Sep 03;21(17):
pubmed: 32899147
Oncogenesis. 2016 Jun 27;5(6):e238
pubmed: 27348268
Front Cell Infect Microbiol. 2021 Sep 22;11:736204
pubmed: 34631604
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Transplant Proc. 2014 Jan-Feb;46(1):40-5
pubmed: 24507023
mSystems. 2020 Dec 8;5(6):
pubmed: 33293403
Cell Rep. 2020 Mar 3;30(9):2934-2947.e6
pubmed: 32130898
Exp Neurol. 2021 Jan;335:113504
pubmed: 33058889
PLoS One. 2013 Sep 10;8(9):e74963
pubmed: 24040367
Adv Nutr. 2019 Jan 1;10(suppl_1):S17-S30
pubmed: 30721960
Nat Commun. 2019 Jul 22;10(1):3273
pubmed: 31332169
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):55-66
pubmed: 27924081
Blood Coagul Fibrinolysis. 2015 Mar;26(2):175-84
pubmed: 25396762
In Vivo. 2002 Mar-Apr;16(2):145-52
pubmed: 12073774
Microbiol Spectr. 2021 Sep 3;9(1):e0053621
pubmed: 34378965
Korean J Pain. 2020 Jan 01;33(1):30-39
pubmed: 31888315
Immun Inflamm Dis. 2021 Dec;9(4):1343-1357
pubmed: 34288545
Eur Respir J. 2019 Mar 28;53(3):
pubmed: 30635296
Mucosal Immunol. 2019 Jul;12(4):843-850
pubmed: 30976087